Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, multicenter phase III trial comparing adjuvant treatment with PegIntron [peginterferon alpha-2b] over 36 months versus reference treatment with IntronA [interferon alpha-2b] over 18 months in cutaneous melanoma patients AJCC stage II (greater than or equal to 1.5 mm clinically node negative)

Next Previous
X
Search
Trial Profile

Randomized, multicenter phase III trial comparing adjuvant treatment with PegIntron [peginterferon alpha-2b] over 36 months versus reference treatment with IntronA [interferon alpha-2b] over 18 months in cutaneous melanoma patients AJCC stage II (greater than or equal to 1.5 mm clinically node negative)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 10 Sep 2012 Results published in the European Journal of Cancer.
    • 12 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top